Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 + T-cell response: A randomized controlled trial

Journal of Infectious Diseases

Volumn 204, Issue 10, 2011, Pages 1532-1540

  Byakwaga, Helen ^a   Kelly, Mark ^b   Purcell, Damian F J ^c   French, Martyn A ^d   Amin, Janaki ^a   Lewin, Sharon R ^e,f,g   Haskelberg, Hila ^a   Kelleher, Anthony D ^a,h   Garsia, Roger ⁱ   Boyd, Mark A ^a   Cooper, David A ^a,h   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b QUEENSLAND HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g BURNET INSTITUTE   (Australia)

^h St Vincent's Centre for Applied Medical Research   (Australia)

ⁱ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD14 ANTIGEN; CD38 ANTIGEN; DIDANOSINE; DNA 16S; HLA DR ANTIGEN; HYPERIMMUNE BOVINE COLOSTRUM; HYPERIMMUNE GLOBULIN; LIPOPOLYSACCHARIDE; PLACEBO; RALTEGRAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULITIS; CLINICAL ASSESSMENT; COLOSTRUM; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UNSTABLE ANGINA PECTORIS;

ADULT; ANIMALS; CATTLE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COLOSTRUM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; LINEAR MODELS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PREGNANCY; PYRROLIDINONES; RNA, VIRAL;

EID: 80054739868     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir559     Document Type: Conference Paper

References (50)

1. Smith C, Sabin C. Lampe F. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003; 17:963-9. (Pubitemid 36549707)
2. Kaufmann G, Perrin L, Pantaleo G. et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-95. (Pubitemid 37248783)
3. Smith K, Aga E, Bosch RJ, et al. Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004; 18:1953-6. (Pubitemid 39313212)
4. Piketty C, Castiel P. Belec L. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998; 12:745-50. (Pubitemid 28190697)
5. Renaud M, Katlama C. Mallet A. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-76. (Pubitemid 29286701)
6. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-8. (Pubitemid 351563833)
7. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006; 166:1632-41. (Pubitemid 44232373)
8. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-4. (Pubitemid 32281572)
9. Kaufmann G, Bloch M, Finlayson R, Zaunders J, Smith D. Cooper D. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16:359-67. (Pubitemid 34165367)
10. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
11. Miller MF, Haley C, Koziel MJ, et al. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: A meta-analysis. Clin Infect Dis 2005; 41: 713-20. (Pubitemid 41170361)
12. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-6. (Pubitemid 46147630)
13. Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005; 191:1670-9. (Pubitemid 40656755)
14. Fernandez S, Price P, McKinnon EJ, Nolan RC. French MA. Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function. Clin Immunol 2006; 120:163-70. (Pubitemid 44080682)
15. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-43. (Pubitemid 36578959)
16. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71. (Pubitemid 44924494)
17. Jiang W, Lederman Michael M, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-85.
18. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIVinfected patients on long-term highly active antiretroviral therapy. AIDS 2008; 22:2035-8.
19. Rajasuriar R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: The role of interleukin 7 and interleukin 7 receptor and microbial translocation. J Infect Dis 2010; 202:1254-64.
20. Chun TW, Justement JS, Pandya P, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 2002; 185:1672-6. (Pubitemid 34587533)
21. Ostrowski S, Katzenstein T. Thim P. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving HAART. J Infect Dis 2005; 191:348-57. (Pubitemid 40139759)
22. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20:1727-36. (Pubitemid 44299364)
23. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
24. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-54.
25. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-9. (Pubitemid 37204311)
26. Casswall TH. Treatment of enterotoxigenic and enteropathogenic Escherichia coli-induced diarrhoea in children with bovine immunoglobulin milk concentrate from hyperimmunized cows: A double-blind, placebo-controlled, clinical trial. Scand J Gastroenterol 2000; 35:711-8. (Pubitemid 30637247)
27. Playford RJ, Macdonald CE. Johnson WS. Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr 2000; 72:5-14. (Pubitemid 30441650)
28. Otto W, Najnigier B, Stelmasiak T. Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Scand J Gastroenterol 2011; 46:862-8.
29. Playford RJ, MacDonald CE, Calnan DP, et al. Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clin Sci 2001; 100:627-33. (Pubitemid 32523315)
30. Bolke E, Jehle PM, Hausmann F, et al. Preoperative oral application of immunoglobulin-enriched colostrum milk and mediator response during abdominal surgery. Shock 2002; 17:9-12.
31. Bolke E, Orth K, Jehle PM, et al. Enteral application of an immunoglobulin-enriched colostrum milk preparation for reducing endotoxin translocation and acute phase response in patients undergoing coronary bypass surgeryda randomized placebo-controlled pilot trial. Wien Klin Wochenschr 2002; 114:923-8. (Pubitemid 35453294)
32. Lissner R, Schmidit H. Karch H. A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7. Infection 1996; 24:378-83. (Pubitemid 26356504)
33. Ng WC, Wong V, Muller B, Rawlin G. Brown LE. Prevention and treatment of influenza with hyperimmune bovine colostrum antibody. PLoS One 2010; 5:e13622.
34. Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ. Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992; 47:276-83.
35. Plettenberg A, Stoehr A, Stellbrink H, Albrecht H. Meigel W. A preparation from hyperimmune bovine colostrum in the treatment of HIVpositive patients with chronic diarrhea. J Mol Med 1993; 71:42-5. (Pubitemid 23041974)
36. Lange J, Gazzard B. Diaz R. Reduced CD4+ T cell decline ad immune activation by NR10057, a specific multi-targeted invention, in HIV-1 positive adults not on antiretroviral therapy (BITE) [abstract H-1230b]. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2000.
37. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-15. (Pubitemid 37070276)
38. Landmann R, Knopf H, Link S, Sansano S, Schumann R. Zimmerli W. Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun 1996; 64:1762-9. (Pubitemid 26129837)
39. Heumann D, Roger T. Initial responses to endotoxins and Gramnegative bacteria. Clin Chim Acta 2002; 323:59-72. (Pubitemid 34804795)
40. Cross AS, Opal SM, Warren HS, et al. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis 2001; 183:1079-86. (Pubitemid 32230956)
41. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE. Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108: 485-93. (Pubitemid 32730795)
42. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1 infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202: 723-33.
43. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-9.
44. Stepanyuk O, Chiang TS, Dever LL, et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 2009; 23:1911-3.
45. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med 2010; 7:e1000321.
46. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009; 106:9403-8.
47. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960-8.
48. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAARTsuppressed subjects. Nat Med 2010; 16:460-5.
49. Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000; 181:141-7. (Pubitemid 30049042)
50. Fernandez S, Nolan RC, Price P, et al. Thymic function in severely immunodeficient HIV type 1-infected patients receiving stable and effective antiretroviral therapy. AIDS Res Hum Retrovir 2006; 22: 163-70. (Pubitemid 43277152)